EnGen Bio Participates in Molecular Pathology Society's 'European AMP 2023'

NGS (Next-Generation Sequencing)-based precision diagnostic platform company NGENBIO (CEO Choi Dae-chul) announced on the 19th that it will participate in the AMP Europe 2023 Congress, held from June 18 to 20 in Milan, Italy, to actively target the European in vitro diagnostics market.

The AMP Europe Congress focuses primarily on molecular diagnostics in the fields of hematopathology, infectious diseases, genetic disorders, and oncology. Both the participants and symposium topics are centered on molecular diagnostics, bringing together clinicians, pathologists, and molecular diagnostic companies from across Europe to actively exchange the latest molecular diagnostic testing methods, technologies, and information.

At this European pathology conference, NGENBIO plans to showcase its CE-IVD certified NGS-based cancer precision diagnostic platform as its main product. The company will discuss directions with local partners regarding the provision of NGS-based cancer precision diagnostic products, clinical trials, and joint development in the European market. In particular, to expand its business in Europe and strengthen connections with local customers, NGENBIO intends to accelerate the search for clinical trial laboratory partners.

NGENBIO’s hematologic cancer NGS precision diagnostic product, ‘HEMEaccuTest™’, recently completed a successful performance evaluation conducted by Labor Volkmann, a diagnostic testing service provider in Germany. The company plans to officially offer hematologic cancer NGS precision diagnostic testing services within Germany and continues to build excellent references in the European NGS diagnostic market.

CEO Choi Dae-chul of NGENBIO stated, “We have expanded the use of our breast cancer precision diagnostic product (BRCAaccuTest™ PLUS) and solid tumor precision diagnostic product (ONCOaccuPanel™) in this important market, which accounts for 30% of global NGS diagnostics, and now we have also expanded the use of our hematologic cancer precision diagnostic product (HEMEaccuTest™).” He added, “We will actively utilize face-to-face partnering meetings with global pharmaceutical and bio companies to promote the excellence of our products and establish ourselves as a leading company capable of driving the local market.”